XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation

Core Viewpoint - XORTX Therapeutics Inc. has received recommendations from independent proxy advisory firms, including ISS, to vote "FOR" the share consolidation at the upcoming shareholder meeting on March 24, 2026, which could enhance the company's long-term growth prospects [1][2]. Share Consolidation - ISS stated that the stock consolidation should have no direct impact on shareholder value and could broaden financing alternatives for the company [2]. - The Board of Directors of XORTX recommends that shareholders vote FOR all proposed resolutions [3][6]. Voting Information - The proxy voting deadline is set for March 20, 2026, and shareholders are encouraged to vote in advance to ensure timely submission [4][6]. - Shareholders of record as of February 20, 2026, are eligible to vote at the meeting [4]. Company Overview - XORTX is a late-stage clinical pharmaceutical company focused on developing therapies for gout and progressive kidney disease, with three clinically advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [5][7]. - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy, targeting purine metabolism and xanthine oxidase to reduce uric acid production [5].